Sue Bell became one of the first Alzheimer's patients in the U.S. to receive the drug now marketed as Leqembi. Her husband ...

Sue Bell was one of the first patients to receive the Alzheimer's drug lecanemab in 2020 as part of the clinical trial. It didn't stop the disease.

Eisai and Biogen have completed their rolling biologics license application in the US for a subcutaneous formulation of Alzheimer's disease therapy Leqembi previously delayed by the FDA on ...

Drug cost-effectiveness organisation ICER has revised its view of Eisai’s new Alzheimer’s disease therapy Leqembi, but has concluded that the price set by the pharma group is still too high.

A woman’s risk for blood clots varied by the type of hormonal contraception used, according to a nationwide cohort study conducted in Denmark.